Microbiota‐derived quinolinic acid is used as an alternative source of replenishing the intracellular NAD+ pool induced by SIRT3 deficiency to regulate intestinal epithelial cell and T cell function, which has implications for targeting intestinal epithelial cells as an approach to the treatment of immune‐associated diseases, including colorectal ...
Ruiying Niu +12 more
wiley +1 more source
Effects of Chinese Medicine on modulating interleukin-17-regulated macrophages in coronary heart disease. [PDF]
Liu Q +6 more
europepmc +1 more source
A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin +4 more
wiley +1 more source
Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland. [PDF]
Kruczek W +7 more
europepmc +1 more source
Tumor evolution in lung adenocarcinoma is shaped by genetic alterations and spatial immune dynamics. By integrating whole‐exome sequencing, imaging mass cytometry, and spatial transcriptomics across two mouse models, this study reveals how mutational burden, immune infiltration, and cell–state interactions evolve during early and late carcinogenesis ...
Bo Zhu +34 more
wiley +1 more source
Brand-to-brand nonmedical switching among interleukin-17 inhibitors or other biologics: Implications of a formulary change. [PDF]
Fendrick AM +5 more
europepmc +1 more source
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia +14 more
wiley +1 more source
Case Report: Secukinumab (Interleukin-17 Inhibitor) and Ulcerative Colitis Flare - the Double-Edged Sword. [PDF]
Ongay J +5 more
europepmc +1 more source
The Fos-related antigen 1–JUNB/activator protein 1 transcription complex, a downstream target of signal transducer and activator of transcription 3, induces T helper 17 differentiation and promotes experimental autoimmune arthritis [PDF]
et al,, Kim, Woo Kyung
core +1 more source

